Abstract
Background: Erlotinib is a tyrosine kinase inhibitor (TKI) approved for 2nd or 3rd line treatment of advanced NSCLC.
Aim: Evaluate the smoking impact on objective response (OR) and survival of pts treated with erlotinib.
Method: Retrospective analysis of OR, overall and post-erlotinib (PE) survival in pts treated with this TKI from 2006 til December 2010, taking into account the gender, smoking status, histology and epidermal growth factor receptor (EGFR) gene mutational status.
Results: Over the past 5 years, 104 pts (57 males) began treatment with erlotinib: 66 adenocarcinomas (AC), 18 squamous cell carcinomas (SCC) and 20 NSCLC. Smoking status: 48 non-smokers (NS); 31 ex-smokers (ES) and 25 active smokers (AS). Median overall survival of 23 months (m). There was no significant difference in overall survival among pts of different gender, staging or smoking status. Median PE survival of 6m. The PE survival was higher in NS (12 vs 6m in ES and 4m in AS; p=0.077), AC (10 vs 5m in SCC and 3m in NSCLC; p=0.013) and in mutated pts (14 vs 6m in non-mutated; p=0.003). Analyzing by histologic subtypes, in AC survival remains higher in NS (21 vs 10m in ES and 2m in AS; p=0.021). Analyzing by mutational status, smoking habits lose significance. Assessing the OR to erlotinib, 50 pts had disease progression and 48 disease control (DC). DC was more frequent in NS (54.2% vs 45.8%; OR=0.476; 95%CI:0.212-1.070) and mutated pts (67.5% vs 32.5%; OR=1.685; 95%CI:0.603-4.707).
Conclusion: Smoking habits have a major impact on survival of AC pts treated with erlotinib. This impact loses significance when analyzed by mutational status.
- © 2011 ERS